| bioMérieux®
INDUSTRY Introduces
BacT/ALERT® Culture Bottles
for Platelet Testing
ST. LOUIS– bioMérieux® INDUSTRY has
announced the introduction of new, FDA-cleared BacT/ALERT®
culture bottles designed for quality control testing of leukocyte-reduced
apheresis platelets. To better meet the stringent demands of blood
centers, bioMérieux has implemented improvements in the
production process and internal quality control standards. For
the new bottles, bioMérieux has instituted 100% quality
control inspection to ensure strict sterility measures are maintained.
The new bottles also feature newly issued product numbers, modified
labeling to help laboratories distinguish between Industry bottles
and Clinical blood culture bottles, and new product inserts specifically
for quality control testing of leukocyte-reduced a apheresis platelets.
These new bottles feature the same media formulation as bottles
currently in use, ensuring continued high performance.
As part of its effort to meet the needs of laboratories throughout
the United States, bioMérieux INDUSTRY has restructured
its sales, marketing and technical service organizations. The
company remains completely dedicated to customer solutions, testing
reliability and customer support.
For more information about the new BacT/ALERT culture bottles
for quality control testing of leukocyte-reduced apheresis platelets,
call bioMérieux INDUSTRY, 1-800-634-7656, prompt 3, or
contact A. C. Marchionne, marketing manager, BacT/ALERT, 314-731-8804.
About bioMérieux INDUSTRY
bioMérieux INDUSTRY provides product solutions to quality
control and research microbiology laboratories. Applications served
include environmental monitoring, sterility testing, pathogen
screening, quality indicators, microbial identification, quality
control organisms, microbial limits and Preservative Effectiveness
Testing.
About bioMérieux
A global leader in disease prevention and management, bioMérieux
provides assays, reagents and instrumentation for clinical microbiology,
coagulation, immunoassay, and nucleic acid diagnostics; and also
for product quality control in the agri-food, cosmetics and pharmaceutical
industries. Based in Marcy-l’Etoile, France, the company’s
U.S. headquarters is in Durham, North Carolina.
With sales of 950 million Euros in 2002, bioMérieux ranks
as the eighth largest
biological diagnostics company worldwide. Over 81% of its activity
takes place on an
international level. Investment in research and development represents
13% of sales.
bioMérieux, employs 5400 people throughout the world,
including 3200 in Europe and 1500 in the US. The group has 15
production sites distributed in France, the United States, Brazil,
Italy and the Netherlands, as well as a European logistics center
in France.
Already present in over 130 countries, with more than 110 distributors
and 32 subsidiaries, bioMérieux continues its international
development by strengthening its presence in Latin America and
Asia.
Return to bioMérieux News |
